Last edited: October 30, 2026
Eine günstige Krankengeschichte kann Hoffnung geben. Als Herbert Eder möchte ich zugleich offenlegen, welche Behandlungen tatsächlich beteiligt waren. Der hier besprochene Colorectal cancer-Fallbericht kombiniert ein Frequenzgerät mit zahlreichen weiteren Maßnahmen und erlaubt deshalb keine eindeutige Zuordnung des Verlaufs zu diesem Gerät.
If you are looking for information on frequency therapy for colorectal cancer, you may come across some impressive case histories. An Australian case report published in 2023 describes a partial remission achieved through a combination of several treatments. It does not demonstrate the independent benefit of the frequency device used. [1]
Das ist für eine persönliche Entscheidung wichtig: Eine erfreuliche Beobachtung verdient Attention, beantwortet aber noch nicht, was bei anderen Patienten zu erwarten ist. Sinnvoll ist deshalb, den berichteten Verlauf, die Aussagekraft der Untersuchung und die heute verfügbaren Behandlungsmöglichkeiten getrennt zu betrachten. So können Sie offen für Forschung bleiben und zugleich konkrete Versprechen prüfen.
What was treated in the patient described
This report concerns a 52-year-old man whose original intestinal tumor had been surgically removed. After liver metastases were detected, he received, among other things, bevacizumab, various infusions, medications, and dietary supplements; later, a Spooky-2 frequency device was added to his treatment. Over the course of treatment, four previously visible liver lesions were no longer detectable, and one remaining lesion had shrunk. The authors reported a stable partial remission and good overall well-being. They also described a decrease in circulating tumor cells in two blood samples taken close together. [1]
Bevacizumab is a targeted antibody that acts against the vascular endothelial growth factor (VEGF). It is part of established cancer treatment and is approved in the EU for metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy. Its mention is therefore not a trivial matter. Treatment without conventional chemotherapy may nevertheless include conventional, tumor-targeted drug therapy. [2]
Für die Bewertung eines Behandlungspakets müssen alle Bestandteile sichtbar bleiben. Fragen Sie bei jeder Erfolgsgeschichte nach Operationen, Medikamenten und Changes des Therapieplans. Erst diese vollständige Übersicht erlaubt überhaupt eine sinnvolle Diskussion darüber, welche Erklärungen für den Verlauf infrage kommen.
Why a favorable course does not indicate a clear cause
A case report describes what was observed in a single individual. A comparative study, on the other hand, seeks to determine the difference between the treatments being investigated. To do so, it requires an appropriate control group. In a randomized study, participants are assigned to groups at random in order to minimize systematic bias as much as possible. Even then, the study’s validity depends on how it is conducted and evaluated. [3]
When multiple measures begin at the same time or overlap, it is impossible to make the crucial comparison for each individual component: What would have happened without it? Chronological sequence alone does not establish a clear cause. One can neither attribute the entire success to any single component nor declare any arbitrarily selected part to be decisive.
Even a mechanism that sounds plausible does not replace this comparison. The question of whether a process is possible under specific experimental conditions is different from the question of whether a specific product or service offers a relevant benefit in everyday life. What matters for your decision is not the length of a list of possible effects, but how thoroughly the claimed benefit has been verified.
Tumor cells, PET, and MRI answer different questions
In oncology, various outcomes are studied: survival time, symptoms, quality of life, time to disease progression, or changes in tumor size. These measures are not interchangeable. An indirect measure requires a sound rationale if it is to be used to infer clinical benefit. The FDA explains these differences in its guidance on endpoints for oncology trials. [4]
A decreasing number of detectable cells in a blood sample therefore does not, in and of itself, prove that fewer metastases will develop in the future or that a person will live longer. Similarly, the statement „no longer visible on this test“ is more limited in scope than the claim „permanently cured.“ What matters is which question the procedure can answer, how reliable the comparison is, and what further monitoring reveals.
When you hear statements like these, ask for clarification on their exact meaning: Was a measurement altered, was a tumor reduced in size, or was a long-term benefit demonstrated in a comparative study? What was defined as “success” beforehand? Who evaluated the images? And how many people were treated in total, including those who did not have a favorable outcome? These questions help you compare the magnitude of a claim with the strength of the evidence.
What treatment options are currently being evaluated for metastatic colorectal cancer
Metastatic colorectal cancer does not present a uniform treatment scenario. In cases of limited spread, surgery or local procedures targeting metastases may, under certain conditions, enable treatment with the goal of a cure. The current ESMO guideline recommends a joint assessment by a specialized tumor board. The sequence of local and systemic treatments also depends on the individual situation. [5]
Factors relevant to drug therapy include mismatch repair or microsatellite status, as well as RAS and BRAF mutations. If molecular test results are appropriate, immunotherapies or targeted drugs may be considered. In addition, combination chemotherapy regimens, the patient’s overall condition, and previous treatments play a role. Therefore, „metastases present“ does not automatically mean that only a single chemotherapy regimen is possible, nor does it mean that all patients can expect the same benefit. [5]
Lassen Sie vor einer weitreichenden Entscheidung klären, ob die nötigen Gewebeanalysen vorliegen und ob die Behandlungsmöglichkeiten vollständig besprochen wurden. Eine fachliche Zweitmeinung ist besonders dann hilfreich, wenn Sie ein empfohlenes Vorgehen ablehnen möchten oder ein kommerzielles Angebot mit angeblich fehlenden anderen Möglichkeiten begründet wird. Fragen Sie konkret nach dem Behandlungsziel und den Alternativen.
High-dose vitamin C: The comparison is more meaningful than the assumption
Die VITALITY-Studie untersuchte bei 442 Menschen mit zuvor unbehandeltem metastasiertem Darmkrebs zusätzliches hoch dosiertes intravenöses Vitamin C zu FOLFOX mit oder ohne Bevacizumab. In der Gesamtgruppe wurde der primäre Endpunkt nicht erreicht: Die Zeit ohne Fortschreiten war nicht signifikant länger. Auch das Gesamtüberleben unterschied sich nicht signifikant. Ein günstiges Signal in der vorab festgelegten RAS-mutierten Untergruppe ist eine begrenztere Aussage und kein Beleg, dass Vitamin C eine Krebsbehandlung ersetzen kann. [6]
Furthermore, intravenous infusions should not be equated with a normal intake of vitamins through food. High doses of vitamin C can pose significant risks, particularly for people with kidney disease, a predisposition to kidney stones, G6PD deficiency, or iron overload. These conditions must be medically evaluated before treatment begins. [7]
The practical question, therefore, is not just whether a substance is „natural.“ Ask about the specific goal, the data relevant to your particular condition, and how potential side effects are monitored. A plausible rationale can justify a study; it does not obligate you to pay for an unproven treatment.
Using Medications Differently: Research Instead of Random Combinations
The ReDO database compiles a list of drugs that were originally developed for other conditions and are being further investigated for their potential effects on cancer. The database operators expressly note that the list is not a collection of treatment recommendations for patients. For many entries, the evidence is still limited. The inclusion of an active ingredient in a research database therefore does not constitute an endorsement of a specific treatment regimen. [8]
Herbal remedies and dietary supplements taken in addition to cancer medications can alter the absorption, metabolism, or excretion of those medications. This may lead to adverse effects or a change in the intended therapeutic effect. Discuss all products with your oncology team and, if necessary, the clinical pharmacy, even if they are available without a prescription. [9]
Please bring a complete list of product names, ingredients, dosages, and times of administration. Also make a note of who recommended each medication. If multiple healthcare providers are involved, it should be clearly agreed upon who will review the overall combination and who will decide on changes if new symptoms arise. This is more helpful than a mere assurance that each individual component is well tolerated.
Research on electromagnetic fields does exist—with specific protocols
As part of the LiveR-F project, Charité is investigating amplitude-modulated radiofrequency fields in combination with trifluridine/tipiracil and bevacizumab in patients with previously treated metastatic colorectal cancer. The study is registered under NCT05991102. The protocol pertains to a precisely defined patient group and a specific combination of treatments; it documents a research question and does not claim any previously established treatment success. [10]
Eine weitere vom US-Krebsinstitut aufgeführte Phase-II-Studie untersucht amplitudenmodulierte Hochfrequenzfelder mit Fruquintinib bei vorbehandelter Erkrankung. Im Protokoll wird ein TheraBionic-Gerät genannt. Unter anderem sollen Überleben und Verträglichkeit beurteilt werden. Auch diese Studienbeschreibung ist kein Ergebnisbericht und lässt sich nicht als Wirksamkeitsbeleg für beliebige Frequenzgeräte verwenden. [11]
If you’re interested in participating, the study center is the right place to start. Ask whether the study is compatible with your previous treatments and test results, what additional burdens it may entail, and what tests are planned. Testing a procedure in a controlled study is different from deriving a general treatment recommendation based on a registry number.
How to Effectively Evaluate an Additional Offer
Ask for a written response addressing three points: What specific benefit are you being promised? Which study involving comparable patients supports this claim? And how will it be determined during treatment whether there are benefits or harms? Insist on clear information regarding total costs, time commitment, and who is responsible.
Eine ergänzende Maßnahme sollte ein nachvollziehbares Ziel haben, etwa Unterstützung bei einer bestimmten Beschwerde. Ob sich Ihr Alltag dadurch verbessert, ist eine wichtige eigene Frage. Daraus lässt sich jedoch nicht automatisch ableiten, dass auch das Tumor growth beeinflusst wird. Halten Sie diese Ziele im Gespräch getrennt, damit ein angenehmer Behandlungstermin nicht unbemerkt zum vermeintlichen Krebsnachweis wird.
To make decisions about your cancer treatment, you need the complete medical report and an honest assessment of the available evidence. Use case reports as a starting point for questions, but don’t interpret them as a personal guarantee of success. Discuss any additional treatments with your care team in advance, and do not change an agreed-upon cancer treatment on your own based on a single patient’s medical history.
My take: All treatments must remain visible
In this case, bevacizumab is a key component of the patient’s medical history and treatment. The antibody targets VEGF and is used in cancer therapy. Presenting this as a success achieved solely through frequency-based treatment would therefore oversimplify the report. [1] [2]
Another important factor in your decision is whether the report describes an imaging finding, a blood test result, or a long-term clinical benefit. These objectives are not interchangeable. I would use such a report as an opportunity to ask questions at the tumor board and request separate evidence of benefit and tolerability for each additional procedure. [4] [5]
Here is an overview of the medical basis Colon Cancer: Diagnosis and Treatment.
I explain how case reports differ from comparative studies under Studies on Frequency Therapy.
Sources and Further Information
- Ried, Eng, and Binjemain: Metastatic Colon Cancer—Integrative Therapies Including Electromagnetic Field Frequencies, Case Report 2023. Retrieved October 28, 2026.
- EMA: Avastin – Mechanism of Action and Approved Indications. Retrieved October 28, 2026.
- University of Oxford, CEBM: Study Designs. Retrieved October 28, 2026.
- FDA: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Retrieved October 28, 2026.
- ESMO: Metastatic Colorectal Cancer – Clinical Practice Guideline, 2026. Retrieved October 28, 2026.
- Wang et al.: VITALITY – High-Dose Vitamin C in Addition to First-Line Therapy for Metastatic Colorectal Cancer, 2022. Retrieved October 28, 2026.
- NCI: Intravenous Vitamin C, Patient Version. Retrieved October 28, 2026.
- ReDO_DB: Research Database on the Repurposing of Drugs, as of October 2026. Retrieved October 28, 2026.
- NCI: Interactions Between Cancer Therapy and Foods and Dietary Supplements. Retrieved October 28, 2026.
- Charité: Study Information LiveR-F, NCT05991102. Retrieved October 28, 2026.
- NCI: AM RF EMF with Fruquintinib, Phase II Trial NCT07130903. Retrieved October 28, 2026.
Topic Overview: Research and Studies.

